Related Experiment Video
Updated: Aug 8, 2025

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
RAS and PP2A activities converge on epigenetic gene regulation
Anna Aakula1, Mukund Sharma1, Francesco Tabaro2
1Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Abstract:
RAS-mediated human cell transformation requires inhibition of the tumor suppressor protein phosphatase 2A (PP2A). However, the phosphoprotein targets and cellular processes in which RAS and PP2A activities converge in human cancers have not been systematically analyzed. Here, we discover that phosphosites co-regulated by RAS and PP2A are enriched on proteins involved in epigenetic gene regulation. As examples, RAS and PP2A co-regulate the same phosphorylation sites on HDAC1/2, KDM1A, MTA1/2, RNF168, and TP53BP1. We validate RAS- and PP2A-elicited regulation of HDAC1/2 chromatin recruitment, of RNF168-TP53BP1 interaction, and of gene expression. Consistent with their known synergistic effects in cancer, RAS activation and PP2A inhibition resulted in epigenetic reporter derepression and activation of oncogenic transcription. Transcriptional derepression by PP2A inhibition was associated with an increase in euchromatin and a decrease in global DNA methylation. Collectively, the results indicate that epigenetic protein complexes constitute a significant point of convergence for RAS hyperactivity and PP2A inhibition in cancer. Furthermore, the work provides an important resource for future studies focusing on phosphoregulation of epigenetic gene regulation in cancer and in other RAS/PP2A-regulated cellular processes.
Insights
RAS hyperactivity and protein phosphatase 2A (PP2A) inhibition converge on epigenetic regulators in human cancers. This convergence impacts gene expression and chromatin states, offering new therapeutic targets for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- RAS-mediated cell transformation necessitates inhibition of the tumor suppressor protein phosphatase 2A (PP2A).
- The specific phosphoprotein targets and cellular pathways influenced by RAS and PP2A in cancer remain incompletely understood.
Purpose of the Study:
- To systematically analyze phosphoprotein targets and cellular processes where RAS and PP2A activities intersect in human cancers.
- To investigate the role of epigenetic gene regulation in the convergence of RAS and PP2A signaling.
Main Methods:
- Phosphoproteomic analysis to identify co-regulated phosphosites.
- Validation of identified phosphoregulation on key epigenetic proteins (e.g., HDAC1/2, RNF168, TP53BP1).
- Assays to assess chromatin recruitment, protein interactions, gene expression, and epigenetic reporter activity.
Main Results:
- Phosphosites co-regulated by RAS and PP2A are significantly enriched in proteins involved in epigenetic gene regulation.
- RAS and PP2A co-regulate phosphorylation sites on epigenetic modifiers including HDAC1/2, KDM1A, MTA1/2, RNF168, and TP53BP1.
- RAS activation and PP2A inhibition lead to epigenetic reporter derepression, oncogenic transcription activation, increased euchromatin, and decreased DNA methylation.
Conclusions:
- Epigenetic protein complexes represent a critical convergence point for RAS hyperactivity and PP2A inhibition in cancer.
- The findings provide a valuable resource for research into phosphoregulation of epigenetic gene regulation in cancer and other RAS/PP2A-related processes.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Spreading of Chromatin Modifications
Writers
The writer...

